|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/14/17 Emmaus Life Sciences, Inc. 10-Q 6/30/17 52:5.4M S2 Filings LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 473K
2: EX-3.1 Articles of Incorporation/Organization or Bylaws HTML 123K
3: EX-4.9 Instrument Defining the Rights of Security Holders HTML 137K
4: EX-10.30 Material Contract HTML 35K
5: EX-31.1 Certification -- §302 - SOA'02 HTML 20K
6: EX-31.2 Certification -- §302 - SOA'02 HTML 20K
7: EX-32.1 Certification -- §906 - SOA'02 HTML 17K
14: R1 Document and Entity Information HTML 42K
15: R2 Unaudited Condensed Consolidated Statements of HTML 68K
Operations
16: R3 Unaudited Condensed Consolidated Balance Sheets HTML 101K
17: R4 Unaudited Condensed Consolidated Balance Sheets HTML 38K
(Parenthetical)
18: R5 Unaudited Condensed Consolidated Statements of HTML 103K
Cash Flows
19: R6 Unaudited Condensed Consolidated Statements of HTML 57K
Stockholders' Deficit
20: R7 Nature of Operations HTML 44K
21: R8 Summary of Significant Accounting Policies HTML 62K
22: R9 Stockholders' Equity HTML 151K
23: R10 Prior Year Revision HTML 35K
24: R11 Related Party Transactions HTML 55K
25: R12 Loss Per Share HTML 42K
26: R13 Commitments and Contingent Liabilities HTML 36K
27: R14 Subsequent Events HTML 30K
28: R15 Summary of Significant Accounting Policies HTML 122K
(Policies)
29: R16 Stockholders' Equity (Tables) HTML 113K
30: R17 Prior Year Revision (Tables) HTML 32K
31: R18 Related Party Transactions (Tables) HTML 36K
32: R19 Loss Per Share (Tables) HTML 41K
33: R20 Commitments and Contingent Liabilities (Tables) HTML 30K
34: R21 Nature of Operations (Details Narrative) HTML 90K
35: R22 Summary of Significant Accounting Policies HTML 72K
(Details Narrative)
36: R23 Stockholders' Equity (Details) HTML 25K
37: R24 Stockholders' Equity (Details 1) HTML 39K
38: R25 Stockholders' Equity (Details 2) HTML 115K
39: R26 Stockholders' Equity (Details 3) HTML 39K
40: R27 Stockholders' Equity (Details 4) HTML 46K
41: R28 Stockholders' Equity (Details Narrative) HTML 491K
42: R29 Stockholders' Equity (Details Narrative 1) HTML 46K
43: R30 Prior Year Revision (Details) HTML 25K
44: R31 Related Party Transactions (Details) HTML 50K
45: R32 Related Party Transactions (Details Narrative) HTML 119K
46: R33 Loss Per Share (Details) HTML 36K
47: R34 Commitments and Contingent Liabilities (Details) HTML 52K
48: R35 Commitments and Contingent Liabilities (Details HTML 51K
Narrative)
49: R36 Subsequent Events (Details Narrative) HTML 89K
51: XML IDEA XML File -- Filing Summary XML 84K
50: EXCEL IDEA Workbook of Financial Reports XLSX 79K
8: EX-101.INS XBRL Instance -- myan-20170630 XML 1.58M
10: EX-101.CAL XBRL Calculations -- myan-20170630_cal XML 120K
11: EX-101.DEF XBRL Definitions -- myan-20170630_def XML 549K
12: EX-101.LAB XBRL Labels -- myan-20170630_lab XML 924K
13: EX-101.PRE XBRL Presentations -- myan-20170630_pre XML 731K
9: EX-101.SCH XBRL Schema -- myan-20170630 XSD 131K
52: ZIP XBRL Zipped Folder -- 0001615774-17-004413-xbrl Zip 131K
EXHIBIT 31.2
Certification of CFO Pursuant to
Securities Exchange Act Rules 13a-14 and 15d-14
as Adopted Pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
I, Donald D’Ambrosio, certify that:
1. I have reviewed this quarterly report on Form 10-Q of MYnd Analytics, Inc..;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
| Date: August 14, 2017 | |
| /s/ Donald D’Ambrosio | |
| Name: Donald D’Ambrosio | |
| Title: Chief Financial Officer (Principal Financial Officer) |
C:
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/14/17 | |||
| For Period end: | 6/30/17 | S-1/A | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/31/22 Emmaus Life Sciences, Inc. 10-K 12/31/21 98:18M ActiveDisclosure/FA 8/10/21 Emmaus Life Sciences, Inc. 10-K/A 12/31/20 92:18M ActiveDisclosure/FA |